REFOCUS GROUP, INC. Inactive Instrument
Refocus Group, Inc. Stock Other OTC
Equities
RFCS
US75865X2027
Biotechnology & Medical Research
Financials (USD)
| Sales 2003 | - | Sales 2004 | - | Capitalization | 2.59M |
|---|---|---|---|---|---|
| Net income 2003 | -5M | Net income 2004 | -3M | EV / Sales 2003 | - |
| Net cash position 2003 | 3 | Net Debt 2004 | 0.28 | EV / Sales 2004 | - |
| P/E ratio 2003 |
-1.51
x | P/E ratio 2004 |
-0.67
x | Employees | - |
| Yield 2003 * |
-
| Yield 2004 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
| Managers | Title | Age | Since |
|---|---|---|---|
J. Michael Judy
CEO | Chief Executive Officer | - | 13-10-27 |
David Schanzlin
CTO | Chief Tech/Sci/R&D Officer | - | 12-01-31 |
Selene A. Burke
CTO | Chief Tech/Sci/R&D Officer | - | 05-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 76 | 10-12-31 | |
Thomas M. Loarie
CHM | Chairman | - | 13-12-31 |
Thomas Lyles
BRD | Director/Board Member | - | 05-02-28 |
Refocus Group, Inc. is a medical device company. The Company is involved in researching and developing treatments for human vision disorders, particularly for the treatment of presbyopia. The Companyâs product, VisAbility Micro Insert System, is a binocular presbyopia treatment, which works outside the visual axis. VisAbility Micro Insert System is under clinical trials in the United States and aims to help patients reduce or eliminate their need for reading glasses.
| 1st Jan change | Capi. | |
|---|---|---|
| +1.55% | 43.84B | |
| +7.17% | 41.68B | |
| +45.26% | 41.25B | |
| -11.96% | 27.04B | |
| +7.60% | 25.53B | |
| -24.32% | 18.18B | |
| -3.11% | 12.29B | |
| +27.79% | 12.29B | |
| +7.73% | 11.15B |
